processed to active cathepsin S at pH 4.5 in the presence of an excess of cysteine and catalytic amounts of dextran sulfate. Active Cat S was used to immunise mice and as a standard for assay calibration curves.
Monoclonal antibodies (MAbs) (Krka, d.d ., Ljubljana, Slovenia) used in ELISA, IHA and Western blots were prepared from mouse hybridoma cell lines (Schweiger et al, 1997; Zavašnik-Bergant et al, 2001 ). The cell culture supernatants were purified by affinity chromatography on protein A-Sepharose as recommended by the producer (Pharmacia, Uppsala, Sweden). Antibody-containing fractions were pooled, dialysed against PBS, pH 7.2, and concentrated to at least 1 mg ml -1 by ultrafiltration. Murine MAb was conjugated to horseradish peroxidase (HRP, Type IV, Sigma, St Louis, USA) using the 2-step glutaraldehyde method (Avrameas et al, 1978) .
Western blot
Proteins were first separated by SDS-PAGE on 8-25% polyacrylamide gels (Pharmacia) using a PhastSystem apparatus and procedure (Pharmacia). After electrophoresis the proteins were transferred to a nitrocellulose membrane (Millipore, Bedford, USA) by passive diffusion. The membrane was first soaked in PBS, + 0.5% Tween 20, pH 7.2 to block non-specific binding and incubated subsequently with primary MAbs, raised against human Cat S. After washing, the membrane was incubated with 1/1000 diluted goat anti-mouse IgG conjugated to HRP (Dianova, Hamburg, Germany). Detection was performed using 0.05% 3,3′-diaminobenzidine tetrahydrochloride (DAB, Sigma) and 0.09% H 2 O 2 in 0.05M Tris-HCl buffer, pH 7.5.
ELISA
The combination of 2B4 MAb and 1E3 MAb (Krka, d.d., Ljubljana, Slovenia) was used to optimise sandwich ELISA. Both antibodies recognise mature and pro-forms of Cat S. Microtitre plates were coated with 10 µg ml -1 of 2B4 MAb in 0.01 M carbonate/bicarbonate buffer, pH 9.4 at 4˚C. After blocking (2% BSA-PBS, 150 µl well -1 ), the samples or Cat S standards were added (100 µl well -1 ). After 2 h of incubation the wells were washed and filled with 1E3 MAb conjugated with HRP. After a further 2 h incubation at 37˚C 200 µg well -1 of peroxidase substrate 3,3′,5,5′-tetramethylbenzidine (TMB, Sigma) 0.012% H 2 O 2 , was added. After 15 min the reaction was stopped by adding 50 µl of 2 M H 2 SO 4 . The amount of degraded substrate, as a measure of bound immunocomplexed Cat S, was determined by absorbance at 450 nm, and the concentration of Cat S calculated from the calibration curve.
IHA of Cat S in tumours, lymph nodes and parenchyma of the lung
Sections (3-5 µm) from formalin-fixed, paraffin-embedded tissues were used for immunohistochemical analysis (Hsu et al, 1981; Kayser and Gabius, 1997) . Tissue sections were deparaffinised by xylene (2 × 5 min) and rehydrated through alcohol 99% (2 × 5 min), 96% (1 × 2 min), 70% (1 × 2 min), 50% (1 × 2 min), to phosphate-buffered saline (PBS), pH 7.4 (3 × 3 min). Tissue sections were incubated with 0.1% trypsin in PBS, pH 7.4, containing 20 mM CaCl 2 , at 37˚C for 30 min. They were then washed in distilled H 2 O (1 × 1 min) and equilibrated in PBS (1 × 5 min). After blocking (i) endogenous peroxidase with 3% methanolic hydrogen peroxide for 15 min, and (ii) non-specific binding sites with 5% normal goat serum in PBS for 30 min at 25˚C, tissue sections were rinsed in PBS (3 × 3 min) and incubated with a monoclonal anti-human Cat S antibody (clones 2B4 and 1E3, Krka, d.d.) diluted to 8 µg ml -1 in PBS containing 5% normal goat serum in a humid chamber at 25˚C overnight. After washing in PBS (3 × 3 min), detection was performed by using the highly sensitive CSA-system (DAKO GmbH, Hamburg, Germany). Briefly, tissue sections were incubated with biotinylated rabbit anti-mouse Ig antibodies in 0.05 M Tris-HCl, pH 7.6 containing 5% normal goat serum. This procedure was followed by sequential 15-minute incubations with streptavidin-biotin-peroxidase complex, biotinylated thyramin-peroxidase complex and streptavidin coupled to peroxidase. After each step tissue sections were washed in PBS (2 × 5 min). Peroxidase activity was developed for 5 min with DAB (0.3 mg ml -1 in 0.05 M Tris-HCl buffer, pH 7.6), including 0.2% hydrogen peroxide. The reaction was stopped by washing the tissue sections in distilled water for 5 min. Finally, tissue sections were lightly counterstained with 5% Harris's haematoxylin, dehydrated and mounted.
The following control assays were performed: (i) pre-adsorption of the antigen with the antibody in a 1:3 molar ratio. Cat S had been inactivated in Tris-HCl buffer, pH 8.2 at 37˚C for 30 min prior incubation with the antibody (Bromme et al, 1989) , (ii) incubation as in the assay, omitting the primary antibody; (iii) incubation omitting secondary antibody, (iiii). All control assays were performed on 2 parallel sections. Tissue sections were inspected by the pathologist of the Thoraxklinik in Heidelberg, Germany (KK), classified into 2 groups and considered positive when > 5% of stained cells (tumour cells, histiocytes, lymphocytes) were present.
Patients, samples
Matched pairs of tumour and adjacent non-cancerous (parenchyma) lung tissue were obtained from 73 patients treated by surgery at the Thoraxhospital Heidelberg-Rohrbach (Germany). 62 were primary non-small-cell lung cancer (NSCLC) tumours and 11 secondary tumours. For 24 patients from this group tumour cell infiltrated and non-infiltrated lymph nodes were also obtained. Tissue cytosols were prepared and protein concentration determined as described (Werle et al, 1995) .
Serum samples were obtained from 148 patients with malignant lung tumours. Sera from 49 patients (33%) were collected before therapy whereas from the rest of the lung cancer patients (n = 99) sera were collected after therapy, all in the year 1997. Out of 148 patients with malignant tumours 57 were adenocarcinoma, 57 small-cell lung cancer (SCLC) and 34 squamous cell type carcinoma. SCLC patients were treated by chemotherapy whereas nonsmall-cell lung carcinoma (NSCLC) patients were treated by surgery followed by chemotherapy and/or radiation therapy depending on the stage of the tumour (Manegold and Drings, 1998; Schraube et al, 1998) .
A control group of sera was collected from 40 healthy donors , matched for gender and age to the patient's population. In all cases the blood (5 ml) was clotted at 4-8˚C, centrifuged at 3000 rpm and sera stored at -70˚C until analysed.
Tissue sections for IHA were prepared from 26 NSCLC tumours (9 adenocarcinoma, 6 squamous cell carcinoma, 6 large cell carcinoma, 5 carcinoids), 7 SCLC tumours, 3 secondary tumours, 6 benign lung tissues and 4 infiltrated and 6 non-infiltrated lymph nodes.
Statistical analysis
For descriptive statistics, SPSS PC software was used (Release 6.0, SPSS Inc, Chicago, IL). For comparing the data of matched pairs of tumour and lung tissue, Wilcoxon's rank test was applied. Differences in Cat S levels (tissue and serum) between various groups of patients and controls were tested by Mann-Whitney and Kruskal-Wallis test. Univariate analysis of survival probability was performed by Kaplan-Meier analysis (Kaplan and Meier, 1958) , using the log-rank test for determining statistical significance between survival curves (Release 6.0, SPSS Inc, Chicago, IL; PC-Statistics, TOPSOFT, Hannover, Germany). Critlevel program (Abel et al, 1984) was used for separating variables into low and high groups. In all tests, 2-sided P values below 5% were considered significant.
RESULTS

Antibody specificity
MAbs used in ELISA and IHA were tested for specificity by Western blots. As evident from Figure 1 , 1E3 and 2B4 MAbs reacted with the mature (28 kDa) and pro-form (36 kDa) of recombinant human Cat S. Pretreatment of both MAbs with the antigen in 1:1 to 1:3 molar ratio resulted in significant decrease of the signal. In tissue cytosols of lung tumours and lymph nodes predominantly the mature form of Cat S was detected (results not shown). MAbs did not react with the related human cathepsins B, H and L.
Cat S protein levels in tissue cytosols and sera, determined by ELISA
A working range of 2-62 ng ml -1 and a detection limit, defined as the concentration corresponding to the mean absorbance of 10 replicates of zero standards plus 3SDs of 0.8 ng ml -1 , were determined from the calibration curve ( Figure 2 ). The intra-assay coefficient of variance (CV), determined by measuring 12 replicates each of low, middle and high controls, varied from 11.5% to 3.8%. Inter-assay precision, determined by evaluating 3 controls in quadruplicate in 10 separate assays, ranged from CV 7.3% to 4.3%. To test the accuracy of ELISA, different amounts of recombinant human Cat S were added to known amounts of Cat S in serum and tissue cytosol samples. Recovery levels were determined by comparing the expected vs observed concentrations and ranged from 85.2% to 116.0% (Figure 2) . Additionally, tissue cytosols and sera were serially diluted to the levels encompassing the range of the assay. The linearity of the response was evaluated by comparing the measured values with the calibration values. The dilution curves for sera and tissue cytosols were linear between 1 : 4 and 1 : 60 (Figure 2 ). The optimal dilution of samples was defined from the linear range of dilution curves. For sera it ranged from 1/4 to 1/30, for tissue extracts from 1/6 to 1/60.
The median levels of Cat S in tumours and adjacent lung tissues of 62 NSCLC patients are shown in Table 1 . The Cat S level is approximately 2 times higher in tumour than control lung tissue. No significant difference was found between adenocarcinomas and squamous cell carcinomas, whereas in secondary tumours the Cat S level was significantly lower than in primary tumours (P = 0.01). Additionally, Cat S levels were not associated with tumour grade or TNM status. In non-invaded lymph node tissue obtained from the same patients the median level of Cat S was 16.6 ng mg -1 of total protein (range 5.4-77.2) whereas in lymph nodes invaded by tumour cells, it was significantly lower-7.5 ng mg -1 (range 2.0-84.0, P < 0.001). Mean values ± 2 SEM are shown in Figure 3 .
In sera the median levels of Cat S were 14.2 ng ml -1 (range 9.1-24.0) for healthy controls and 13.1 ng ml -1 (range 8.0-28.5) for patients with malignant disease. For both groups no association with age or gender has been observed. The difference was neither significant between the control group and patients with malignant disease nor between groups with different histologies or between pre-therapy and post-therapy sera.
IHA
Immunohistochemical staining of lung parenchyma, regional lymph nodes and lung tumours of different origin is shown in Figure 4 . The location of Cat S in an alveolus is seen in Figure 4A , B, where a brown staining reaction is visible in alveolar type II cells and macrophages. The enzyme shows a lysosomal distribution over the cytoplasm. In addition, we observed different staining intensity of Cat S in macrophages as well as in alveolar type II cells. Immunoreactive Cat S was not found in alveolar type I cells. Furthermore, Cat S was present in a high concentration also in bronchial epithelial cells, showing either a lysosomal distribution or a more restricted localisation in the basal proliferating zone of the epithelium. The analysis of infiltrated regional lymph node tissue revealed a strong staining of Cat S in lymphocytes whereas in non-infiltrated tissue Cat S was stained in lymphocytes and histiocytes, most likely macrophages. Cat S can also be detected in lung tumours, independently of their origin. We found a positive reaction in adenocarcinomas, squamous cell carcinomas and small cell carcinomas. Remarkably, a weak-positive reaction at the sites of interaction between tumour cells of the small cell carcinoma and the extracellular matrix of the alveoli could be observed. Correlation of Cat S staining (positive vs. negative) with clinico-pathological parameters of NSCLC patients is shown in Table 2 . No significant correlation between Cat S level and grading or tumour stage has been observed. Table 3 shows IHA of Cat S in lung tumours, secondary tumours, benign lung tissue and infiltrated and noninfiltrated lymph nodes with regard to staining intensity in tumour cells, histiocytes and lymphocytes.
Survival analysis
Cat S levels in tumour tissue cytosols and adjacent control lung parenchyma from 60 patients with NSCLC were included in univariate survival analysis. Median follow-up of the observed tumour patients was 3.0 years (25th percentile: 1.09 years). Cutoff values of 5.0 ng mg -1 for tumour tissue and 0.5 ng mg -1 for lung tissue have been optimised using the Critlevel program (Abel et al, 1984) . In both groups, patients with the levels above the cutoff values experienced significantly better survival probability than the patients with lower Cat S levels (P = 0.025 -tumours; 
P<0.01
Figure 3 Cat S levels in tumours, control lung tissue and lymph nodes of patients with lung cancer (n = 29). Error bars represent 2 SEM P = 0.02 -parenchyma) ( Figure 5 ). In addition, survival curves are significantly separated in the first 2 years of follow-up.
DISCUSSION
Lysosomal cysteine proteinases are known to mediate intracellular protein turnover, regulating the lifetime of proteins critical for normal cell function. They are also involved in specific processing steps for smaller peptides, pro-hormones and pro-enzymes (Uchiyama et al, 1994) . Some cysteine proteinases such as Cats B, L and H, are expressed in almost all cells, suggesting a housekeeping function in protein turnover, whereas the expression of others, e.g. Cats S, K and V is restricted to particular tissues and cells, indicating more specific roles in cell physiology. Cat S is distinguished from the other members of papain superfamily by its high stability at neutral pH and expression, restricted to lymphatic tissues and antigen-presenting cells (Wiederanders et al, 1991; Brömme et al, 1994) . Some of the specific properties are consistent with subtle structural differences found in the active site of Cat S by crystal structure analysis (McGrath et al, 1998; Gunčar et al, 1999) . Due to the localisation in lymphatic tissues and cells it was suggested that Cat S is involved in modulating the immune response (Chapman et al, 1997; Kirschke et al, 1998) . Its specific role in processing the invariant chain (Ii) designates this enzyme as a potentially useful therapeutic target in diseases associated with a hyperimmune response, such as asthma, hypersensitive pneumonitis and autoimmune disorders (Chapman et al, 1997) . Since there is an increasing body of evidence that impaired antigen-processing might also be associated with malignant transformation and escape of tumour cells from recognition by T cells (Seliger et al, 2000) , the knowledge on tumour Cat S could help to characterise the molecular mechanisms regulating presentation of tumour-associated antigens (TAA).
On the other hand, Cat S expresses broad endopeptidase activity at neutral pH, so one may expect it to play a role in extracellular tissue remodelling associated with tumour invasion and metastasis. Indeed, in our previous study we found that the increased activity of Cat S is associated with lung tumours (Werle et al, 1999) . Quantitative determination of the protein levels of Cat S should provide additional insight into the role of this enzyme in malignant processes. For this reason we have developed a quantitative ELISA, using 2 monoclonal antibodies recognising distinct epitopes on Cat S molecule. Both MAbs, 1E3 and 2B4, used in the assay recognize the pro-form (36 kDa) and the mature form (28 Figure 5 Prognostic significance of Cat S levels in parenchyma (A) and tumours (B) of lung cancer patients. Patients with Cat S levels below cut-off value had a significantly shorter overall survival (s deceased patients, uncensored data; + still living patients, censored data) than patients with Cat S levels above cut-off value (q deceased patients, uncensored data;+ still living patients, censored data) kDa) of recombinant and natural antigen as shown by Western blot analysis. The new ELISA enables reliable and accurate quantification of Cat S in tissue cytosols and sera of lung cancer patients. The levels of Cat S found in lung tissue and lymph nodes agree well with previous reports on the higher expression of this enzyme in lymphatic tissues. Its mean level was 5 times higher in lymph nodes than in lung parenchyma. The levels of Cat S in tumour tissues were found to be higher than those in control parenchyma from the same patients, revealing a possible role for this enzyme in tumour growth and progression. However, serum levels of Cat S were not significantly changed from control levels in patients with malignant disease. Although in our previous report we showed also an increased enzymatic activity of Cat S in lung tumours (Werle et al, 1999) , it seems that Cat S is not involved in tumour development and progression to the same extent as are the related cysteine proteinases Cats B and L. These are significantly overexpressed in lung tumours, released to the extracellular space and participate in degradation of extracellular matrix proteins (Kos and Lah, 1998) . The lack of any correlation of Cat S activity or protein levels with clinical and pathological parameters indicating tumour progression, is consistent with the latter conclusion. In IHA, a positive immunostaining reaction in tumour tissue was observed not only in tumour cells but also in epithelial cells, histiocytes and infiltrated lymphocytes, which may all significantly contribute to the higher overall Cat S protein content and activity. In normal lung tissue a significant staining reaction was observed in alveolar type II cells and macrophages and in bronchial epithelial cells. Its localisation in the basal proliferating zone of the epithelium is consistent with the proposed role of this enzyme in the motility of cilia of conducting lung airway cells (Chapman et al, 1997) .
Cat S protein levels in infiltrated lymph nodes revealed a significant decrease compared with non-infiltrated lymph nodes. By contrast, the Cat B level was the highest in infiltrated lymph nodes, as shown in our previous study (Werle et al, 2000) . From IHA it is evident that Cat S staining in regional lymph nodes is the most extensive in lymphocytes and histiocytes whereas Cat B was predominantly present in tumour cells, partially in histiocytes and absent in lymphocytes. Lower levels of Cat S could be related to the lower expression in affected lymphoid tissue or to the lower number of lymphatic cells. A tumour-directed immune response usually results in enlargement of lymph nodes as a consequence of the increase of the number of lymphoid cells (Lores et al, 1998) . However, this vigorous process is limited to the early growth of tumours and is soon down-regulated, permitting progressive tumour growth and proliferation (Barna and Deodhar, 1975) .
There is growing evidence that CD4 + T cells play a central role in initiating and effecting antitumour immunity. TAA can be presented to CD4 + T cells by professional APCs cells as well as by MHC class II + tumour cells. For direct antigen presentation these tumour cells must leave primary tumour site and enter the lymphatic system and draining lymph nodes. The expression of MHC class II molecules in tumour cells varies among different tumour types and has been associated with both, poor and good prognosis of cancer patients (Seliger et al, 2000) . The expression of other proteins involved in class II antigen presentation and their relation to the course of disease have not been systematically analysed. We have no direct evidence that Cat S is involved in regulation of antitumour immunity, however, we may speculate that its high expression in potential APCs could be beneficial for cancer patients. The latter is consistent with the survival analysis of Cat S in lung cancer patients. It confirmed different pattern for Cat S compared with other cathepsins. Numerous clinical studies on different cancer types have provided evidence that patients with high levels of Cats B and L show higher risk of relapse or death . In contrast, in this study patients with high levels of Cat S experienced significantly better survival probability than those with low levels of Cat S. Prognostic value was defined not only for tumour samples but, even more significantly, for control lung parenchyma. The latter further indicates that increased expression of Cat S is not linked just to the tumour cells and their proliferation and invasion but merely reflects defence mechanisms leading to the regression of malignant disease and better outcome of cancer patients.
In conclusion, the results of our study reveal an increased expression of Cat S in lung tumours. Its role, however, does not seem to be pivotal in remodelling extracellular matrix proteins, resulting in tumour growth, proliferation and metastasis. Its high expression in lymphocytes and histiocytes, decreased levels in infiltrated lymph nodes and a correlation of low levels with poor patient survival, could be related to the modulation of antigen presentation and consequently the response to tumour antigens in cancer patients. G1/2  8  5  3  G3  18  9  9  pT1  3  1  2  pT2  16  10  6  pT3  4  3  1  pT4  3  2  1  pN0  15  10  5  pN1  4  2  2  pN3  0  0  0  pTNM I  8  5  3  pTNM II  2  1  1  pTNM IIIa  9  6  3  pTNM IIIb  1  1  0  pTNM IV  6  3  3 Tissue sections were considered positive when more than 5% of cells were stained. The tumour disease stage was classified according to the international staging system (Hermanek and Sobin, 1987) .
